|Beigene Co. Ltd., of Beijing||Tislelizumab||IgG4 anti-PD-1 monoclonal antibody||Solid and hematologic cancer||China's NMPA approved manufacturing of commercial supply for Chinese market at biologics facility in Guangzhou|
|Cansino Biologics Inc., of Tianjin, China||Convidecia (Ad5-nCoV)||Recombinant adenovirus type-5 vector vaccine||COVID-19 infection||Instituto de Salud Pública de Chile granted emergency use authorization of single-dose vaccine|
|Cytodyn Inc., of Vancouver, Wash.||Leronlimab||CCR5 antagonist||COVID-19 infection||Drug provided to Philippine hospital under compassionate special permit for 28 people critically ill with infection|
|Gilead Sciences Inc., of Foster City, Calif.||Trodelvy (sacituzumab govitecan-hziy)||Trop-2-directed antibody/topoisomerase inhibitor conjugate||Breast cancer||FDA granted full approval to treat adults with unresectable locally advanced/metastatic triple-negative disease who received 2 or more systemic therapies|
|Immutep Ltd., of Sydney||Eftilagimod alpha (IMP-321)||LAG-3 protein||Head and neck cancer||FDA granted fast track designation to treat first-line recurrent/metastatic disease|
|Teva Pharmaceuticals Europe, unit of Teva Pharmaceutical Industries Ltd., of Tel Aviv, Israel||Seffalair Spiromax/Bropair Spiromax (salmeterol xinafoate + fluticasone propionate)||Beta 2 adrenoceptor agonist + glucocorticoid receptor agonist||Asthma||EU granted marketing authorization as maintenance treatment for adults and adolescents 12 years and older|
For more information about individual companies and/or products, see Cortellis.